Grupos de investigación

Publicaciones 2010-2012

Publicaciones anteriores

  1. “Effect of VIP on the balance between cytokines and master regulators of activated helper T cells”. Jimeno R, Leceta J, Martínez C, Gutiérrez-Cañas I, Pérez-García S, Carrión M, Gomariz RP, Juarranz Y. Immunol Cell Biol. 2012 Feb;90(2):178-86.
  2. “Mapping the CRF-urocortins system in human osteoarthritic and rheumatoid synovial fibroblasts: effect of vasoactive intestinal peptide”. Pérez-García S, Juarranz Y, Carrión M, Gutiérrez-Cañas I, Margioris A, Pablos JL, Tsatsanis C, Gomariz RP. J Cell Physiol. 2011 Dec;226(12):3261-9.
  3. “RNA sensors in human osteoarthritis and rheumatoid arthritis synovial fibroblasts: immune regulation by vasoactive intestinal peptide”. Carrión M, Juarranz Y, Pérez-García S, Jimeno R, Pablos JL, Gomariz RP, Gutiérrez-Cañas I. Arthritis Rheum. 2011 Jun;63(6):1626-36. PDF
  4. “Differential expression pattern of pituitary adenylate cyclase-activating polypeptide (PACAP) alternative splicing variants and its receptors in the immune system of rainbow trout (Oncorhynchus mykiss)”. Lugo JM, Tafalla C, Leceta J, Gomariz RP, Estrada MP. Fish Shellfish Immunol. 2011 Feb;30(2):734-8.
  5. “CXCL12 gene expression is upregulated by hypoxia and growth arrest but not by inflammatory cytokines in rheumatoid synovial fibroblasts”. Santiago B, Calonge E, Del Rey MJ, Gutiérrez-Cañas I, Izquierdo E, Usategui A, Galindo M, Alcamí J, Pablos JL. Cytokine. 2011 Feb;53(2):184-90.
  6. “The impact of stress on tumor growth: peripheral CRF mediates tumor-promoting effects of stress”. Arranz A, Venihaki M, Mol B, Androulidaki A, Dermitzaki E, Rassouli O, Ripoll J, Stathopoulos EN, Gomariz RP, Margioris AN, Tsatsanis C. Mol Cancer. 2010 Sep 27;9:261. PDF
  7. “New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes”. Jimeno R, Gomariz RP, Gutiérrez-Cañas I, Martínez C, Juarranz Y, Leceta J. Immunol Cell Biol. 2010 Oct;88(7):734-45.
  8. “Peptides targeting Toll-like receptor signalling pathways for novel immune therapeutics”. Gomariz RP, Gutiérrez-Cañas I, Arranz A, Carrión M, Juarranz Y, Leceta J, Martínez C. Curr Pharm Des. 2010;16(9):1063-80.